NDAORALCAPSULE
Approved
Dec 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EMCYT (estramustine phosphate sodium) by Pfizer. Approved for prostate cancer. First approved in 1981.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EMCYT (estramustine phosphate sodium) is an oral small-molecule chemotherapy combining estrogen and nitrogen mustard, approved in 1981 for metastatic prostate cancer. It functions as a microtubule-targeting agent that disrupts cellular division in hormone-sensitive and castration-resistant disease. The drug represents an older generation of prostate cancer therapy now facing significant competition from modern androgen receptor inhibitors and kinase inhibitors.
$43,000Part D
LOE ApproachingDeclining
<0.1% of prostate cancer market
Minimal commercial infrastructure; supporting roles focus on legacy patient retention and off-label advocacy rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Career Relevance
Working on EMCYT offers limited career acceleration; the product is in terminal decline with minimal market presence and zero new job creation. Professionals assigned to this product should view it as a stabilization/legacy management role, not a growth opportunity, and plan transition to Pfizer's high-priority oncology or specialty care franchises such as IBRANCE, newer checkpoints, or cell therapies.
Worked on EMCYT at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.